FDA-approved
Sexual & reproductive
Bremelanotide
Evidence
FDA approved
Class
Melanocortin receptor agonist
KEY TAKEAWAY
Bremelanotide is a melanocortin receptor agonist approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is used as needed about 45 minutes before sexual activity.
Written by the Veylo editorial team · Updated
November 2026
What it is
A melanocortin receptor agonist acting on the brain
Approved for
Hypoactive sexual desire disorder in premenopausal women
Key fact
Increased desire scores compared with placebo in phase 3 trials
Route
Injection before activity
Evidence strength
FDA approved
Bremelanotide, sold as Vyleesi, is a synthetic peptide related to alpha-MSH, delivered with an autoinjector.
It activates melanocortin receptors in the brain, which are involved in sexual desire and arousal.
The FDA approved bremelanotide in 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Treatment of low sexual desire that causes distress in premenopausal women, when not explained by another condition.
Nausea is the most common effect. Flushing, headache and a short-lived rise in blood pressure can occur. Skin darkening has been reported.
Kingsberg SA et al. Bremelanotide for the treatment of hypoactive sexual desire disorder. Obstet Gynecol. 2019;134:899-908.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.